Latest news with #DishmanCarbogenAmcis'
Business Upturn
13-06-2025
- Business
- Business Upturn
Dishman Carbogen clears US FDA inspection at Naroda facility with no observations
By Aman Shukla Published on June 13, 2025, 12:55 IST Dishman Carbogen Amcis Ltd has announced the successful completion of a scheduled US FDA inspection at its Naroda facility in Ahmedabad. The inspection, which was planned from June 9 to June 13, 2025, was concluded early on June 12, 2025, without any observations or issuance of Form 483. This outcome confirms that no compliance concerns were identified by the US health regulator, reaffirming the company's strong commitment to global regulatory standards and quality systems. With this development, Dishman Carbogen Amcis' facilities at Naroda and Bavla in India, along with its group facilities in Switzerland and the Netherlands, remain in good standing with the US FDA. This reinforces the company's reputation as a reliable global player in the pharmaceutical contract development and manufacturing organization (CDMO) space. The company expressed its appreciation to all employees involved and reiterated its dedication to maintaining the highest standards in quality and compliance. This successful audit outcome is expected to boost customer confidence and support future business growth, especially in regulated markets like the United States. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
06-06-2025
- Business
- Business Standard
Carbogen Amic AG to co-invest in its manufacturing sites in Switzerland
Dishman Carbogen Amcis' wholly owned subsidiary, CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced a strategic co-investment of more than CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at its sites in Aarau and Neuland, Switzerland. The investment will support the production of a drug linker for a commercial antibody-drug conjugate (ADC), enabling CARBOGEN AMCIS to meet rising global demand. As part of the agreement, both facilities will see significant equipment and infrastructure enhancements, including: Aarau site: installation of 850-litre reactors and 0.4 m agitated filter dryers with supporting equipment. Completion is expected by Q1 2027. Neuland site: installation of 850-litre reactors and 0.4 m agitated filter dryers with auxiliary systems. Completion is anticipated by Q3 2027. This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021 to develop a site extension at the Bubendorf site in Switzerland, reinforcing the strength of the relationship and their shared commitment to long-term growth.
